Log in

KTTA Pasithea Therapeutics Corp. NASDAQ · United States

Pasithea Therapeutics (KTTA) news KTTA offering and Nasdaq notice news

Latest Pasithea Therapeutics news

  1. Listings

    Pasithea receives Nasdaq extension to regain bid price compliance

    Nasdaq granted Pasithea Therapeutics 180 more days, to February 16, 2027, to regain the $1.00 minimum closing bid price required for continued listing.

  2. Company Updates

    Pasithea names Kartik Krishnan chief medical officer

    Kartik Krishnan, M.D., Ph.D., became chief medical officer on May 1, 2026, and will oversee clinical development and medical strategy for PAS-004.

  3. Listings

    Pasithea Therapeutics gets Nasdaq notice for trading below $1.00 bid price

    The company has until December 22, 2025 to regain compliance. It may qualify for a second 180-day period and is considering its options.

  4. Financings

    Pasithea Therapeutics files for share and warrant offering, later prices at $1.40

    The May 1, 2025 registration statement covered up to 3,246,753 shares at an assumed $1.54. The deal priced on May 6, 2025 at $1.40 for 3,571,428 shares or pre-funded warrants.

Pasithea Therapeutics annual financials

LineFY2025FY2024
Research and development$8.0 million$7.2 million
Net income (loss)-$20.4 million-$13.9 million
Cash from operations-$15.2 million-$13.9 million
Cash and equivalents$55.2 million$6.9 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $45.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Pasithea Therapeutics

Has Pasithea Therapeutics raised money recently?

Our latest story on this, dated May 1, 2025: "Pasithea Therapeutics files for share and warrant offering, later prices at $1.40". The story links the filing or release it is based on. Read the story.

Has Pasithea Therapeutics received a Nasdaq deficiency notice?

Our latest story on this, dated Jun 27, 2025: "Pasithea Therapeutics gets Nasdaq notice for trading below $1.00 bid price". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Pasithea Therapeutics?

Pasithea Therapeutics Corp. trades under the ticker KTTA on NASDAQ.

Where is Pasithea Therapeutics listed?

Pasithea Therapeutics Corp. is listed on NASDAQ.

What is the SEC CIK of Pasithea Therapeutics?

The SEC Central Index Key (CIK) for Pasithea Therapeutics Corp. is 1841330. Its filings are on SEC EDGAR.

How many shares does Pasithea Therapeutics have outstanding?

33,414,448 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Pasithea Therapeutics listed under?

Our directory records Pasithea Therapeutics Corp. under United States.

What does Pasithea Therapeutics do?

Our directory classifies Pasithea Therapeutics Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Pasithea Therapeutics?

The ISIN recorded for Pasithea Therapeutics Corp. is US70261F2020.

Does aibio.space cover Pasithea Therapeutics?

aibio.space lists Pasithea Therapeutics Corp. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Pasithea Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

Is Pasithea Therapeutics profitable?

Pasithea Therapeutics Corp. reported a net loss of $20.4 million for the fiscal year ended Dec 31, 2025, and used $15.2 million of cash in operations, per its annual report to the SEC.

How much does Pasithea Therapeutics spend on research and development?

$8.0 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Pasithea Therapeutics have?

$45.7 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Pasithea Therapeutics (KTTA) stock news?

Our latest story on Pasithea Therapeutics, dated Sep 16, 2026: "Pasithea warrants to expire on September 17, 2026". Pasithea Therapeutics said its KTTAW warrants will expire on September 17, 2026 and stop trading on Nasdaq, while its common stock keeps trading as KTTA. Source.

Investor discussion: Pasithea Therapeutics

Members talk about Pasithea Therapeutics (KTTA). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Pasithea Therapeutics, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source

  2. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source

  3. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  4. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  5. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  6. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  7. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  8. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  9. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source

  10. Financings

    Reported a financing. SEC Form 424B4. Source

  11. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

  12. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source

  13. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  14. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  15. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  16. Financings

    Reported a financing. SEC Form S-1. Source

  17. Legal

    Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source

  18. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:KTTA on TradingView.

SEC filings and registration

SEC name
Pasithea Therapeutics Corp.
CIK
1841330
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
KTTA (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL, 33139
Phone
(702) 514-4174
Shares outstanding
33,414,448 as of 2026-08-12 (10-Q filed 2026-08-14)

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-09-16
  • 8-K filed 2026-09-09
  • 8-K filed 2026-08-21
  • 10-Q filed 2026-08-14
  • DEF 14A filed 2026-08-07
  • 10-Q filed 2026-05-15
  • 8-K filed 2026-05-04
  • 10-K filed 2026-03-30

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Pasithea Therapeutics Corp. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KTTA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Pasithea Therapeutics Corp.
Ticker
KTTA
Listing
NASDAQ
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US70261F2020
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.